EditorialReducing the burden of disease and death from familial hypercholesterolemia: A call to action
Section snippets
Disclosures
Dr Knowles, Dr O'Brien, Ms Greendale, Ms Wilemon, Dr Genest, Dr Sperling, and Dr Khoury have no relevant disclosures to report. Dr Rader reports consulting for Aegerion, Alnylam, and Sanofi (all modest) and investing on a patent licensed by Penn to Aegerion (significant). Dr Neal has no disclosures.
Dr Knowles had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Disclaimer
The findings and conclusions in this report are those of the authors and do not represent the official position of the Centers for Disease Control and Prevention or the US Department of Health and Human Services.
Sources of Funding
There are no sources of funding to report.
Acknowledgements
We would like to thank Debra Duquette, MS, CGC from Michigan Department of Community Health, Lansing, MI for helpful comments.
References (42)
- et al.
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
J Clin Lipidol
(2011) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
Atherosclerosis
(2004)Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states
Lancet
(1969)- et al.
Familial hypercholesterolemias: prevalence, genetics, diagnosis, and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
J Clin Lipidol
(2011) - et al.
Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment
Atherosclerosis
(2012) - et al.
Implementation of lipid screening guidelines in children by primary pediatric providers
J Pediatr
(2014) - et al.
Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy
Rev Esp Cardiol (Engl Ed)
(2008) - et al.
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
Lancet
(2001) - et al.
A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia
Int J Cardiol
(2013) - et al.
Benefits of the MEDPED treatment support program for patients with familial hypercholesterolemia
J Clin Lipidol
(2009)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society
Eur Heart J
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Eur Heart J
Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia
Circulation
Exome sequencing identifies rare alleles contributing to the inherited basis of early-onset myocardial infarction. Abstract presented at: American Heart Association Scientific Sessions; November 16-20, 2013; Dallas, TX
Circulation
Heart disease and stroke statistics—2013 update: a report from the American Heart Association
Circulation
Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication
J Clin Endocrinol Metab
Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review
Am J Epidemiol
The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein
Annu Rev Genet
Discovery and refinement of loci associated with lipid levels
Nat Genet
Familial hypercholesterolemia
Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2011-2012
NCHS Data Brief
Cited by (49)
Current RNA strategies in treating cardiovascular diseases
2024, Molecular TherapyA Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021
2023, Current Problems in CardiologyImproving Cholesterol Screening in Children—Is Educating Primary Care Providers Enough?
2022, Journal of PediatricsDeveloping implementation strategies to improve uptake of guideline-recommended treatments for individuals with familial hypercholesterolemia: A protocol
2020, Research in Social and Administrative PharmacyCitation Excerpt :Heterozygous FH is defined as having a causative variant in one of the FH-related genes and homozygous FH as having two variants in one of the genes. However, as many as 90% of individuals with FH are undiagnosed.4 Early identification of individuals with FH is key to reducing cardiovascular (CV) events.
Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype
2020, AtherosclerosisCitation Excerpt :Familial hypercholesterolemia (FH) is an inherited autosomal dominant disorder associated with high incidence of atherosclerotic cardiovascular diseases (ASCVD) [1].